Annual Report of the Company for the F.Y.2024-25
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has filed its Annual Report for FY 2024-25 along with the notice of its 32nd AGM, scheduled for September 20, 2025 at 11:30 AM via video conferencing. Revenue from operations grew 12.5% to Rs. 921.93 crores (from Rs. 819.37 crores in FY24), while EBITDA rose to Rs. 155.46 crores and Profit After Tax climbed to Rs. 106.48 crores (up from Rs. 94.75 crores). EPS stood at Rs. 20.99 versus Rs. 19.59 the previous year, with EBITDA margin of 16.86% and PAT margin of 11.55%. The Board did not recommend any dividend, opting to retain earnings to fund expansion. Key strategic moves include acquiring 100% global rights to novel antibiotic Enmetazobactam (EXBLIFEP/Orblicef) via the Allecra Therapeutics acquisition, NCLT approval for the merger with Dhanuka Laboratories, USFDA inspection clearance with VAI status, and ongoing capex on a Rs. 600 crore 7-ACA facility in Jammu.
Shareholders get to review a year of solid revenue and profit growth with improving margins, but no dividend payout means returns depend solely on capital appreciation. The Enmetazobactam homecoming, Dhanuka merger progress, and USFDA clearance strengthen long-term growth prospects, though near-term antibiotic pricing pressure and large capex commitments remain watchpoints.